

TAB B

Date : 17.09.2015

**CURRICULUM VITAE****Name :** Dr. Lill**Forename :** Norbert**Date of Birth :** 13.03.56**Nationality :** German**1. EDUCATION**

- |             |   |  |
|-------------|---|--|
| 1992 - 2012 | : | Qualified person for manufacturing of drug products (§15 AMG, Herstellungsleiter)  |
| 1990 – 1994 | : | Continued education for specialist in pharmaceutical analytics (State Chamber of Pharmacists, Hesse) with the degree Pharmacist for Pharmaceutical Analytics   |
| 1988 – 1990 | : | Continued education for specialist in pharmaceutical technology (State Chamber of Pharmacists, Hesse) with the degree Pharmacist for Pharmaceutical Technology |
| 1985        | : | PhD, University of Regensburg  |
| 1981 - 1985 | : | Post-Graduate student in Pharmaceutics, University of Regensburg, Germany  |
| 1981        | : | License as pharmacist (Approbation)  |
| 1976 – 1980 | : | Undergraduate education as Pharmacist, University Regensburg, Germany  |
| 1966 - 1975 | : | Secondary School (Gymnasium) in Weiden, Germany  |

**2. LANGUAGES**

- |                              |   |         |
|------------------------------|---|---------|
| Mother tongue                | : | German  |
| Fluent professional practice | : | English |
| Basic:                       | : | French  |

Sanofi v Eli Lilly

PTX-691

Date : 17.09.2015

**3. PROFESSIONAL EXPERIENCE WITHIN THE GROUP**

- 2014 until now
- Sanofi-Aventis Deutschland GmbH  
Global Head Pharmaceutical Excellence and  
Drug Device Combination Integrator  
Member of PSO Board.
- Troubleshooting and risk mitigation of late stage projects: integrated development of drug device combination products*
- 2013 - 2014 :
- Sanofi-Aventis Deutschland GmbH  
Head Pharmaceutical Sciences Operations Frankfurt  
Member of PSO Board. Integration of Industrial Development & Innovation (ID&I) Injectables Group. Reorientation of department towards additional industrialization support until product launch. PAI support for Lixisenatide. Fostering further cooperation with IA Frankfurt sites. Development of governance model. Continuation as R&D representative for Device Development Industrialization Launch Preparation Committee (DDIC) and Risk Management Board (RMB) since 2009. Repositioning for Peptide depot delivery systems development.
- 2005 - 2012 :
- Sanofi-Aventis Deutschland GmbH  
Head Pharmaceutical Sciences Department, Northern Europe
- Management of Alnwick (2005), Budapest and Frankfurt site. Member of PSD board. First regular chair of Regional Scientific Management Committee in preclinical and regional CMC project council in CMC for Northern Europe Region. R&D representative for Device Development Industrialization Launch Preparation Committee (DDIC) and Risk Management Board (RMB) since 2009. Hiring and integration of ~30 new associates (~15 PhDs) in FF and BU. Fostering internalization of new technologies (Nanocrystals; ELAN; Microspheres; BROOCKWOOD). Introducing pharmaceutical engineering into organization. Ensuring high standard in GMP and HSE without critical findings in internal and external audits (authorities). Enhancing cooperation with Discovery. Initiating close cooperation with IA PCII. Fostering creating new state-of-the-art parenteral pilot plant; refurbishing of radio-active clinical supply unit (BEX) and creation of new OEB4 area (HSE). Closing of Alnwick (2006) and Budapest (2012) site*
- 2003 - 2004 :
- Aventis Pharma Deutschland GmbH  
Head Pharmaceutical Sciences, Germany
- Introduction of early formulation concept. Fostering transfer, submission and world-wide launch of Apidra as well as Pre-approval inspection (PAI) by FDA*

Date : 17.09.2015

- 2001 - 2002 : Aventis Pharma Deutschland GmbH  
Pharmaceutical Sciences  
Head Drug Delivery Liquids Development
- 1998 - 2000 : Hoechst Marion Roussel, Germany, Frankfurt  
Pharmaceutics Germany  
Head Drug Delivery Liquids  
  
*Transfer, submission and world-wide launch of Lantus®. Pre-approval inspection (PAI) by FDA*
- 1994 – 1998 : Hoechst Marion Roussel , Germany, Frankfurt  
Pharmaceutics Department  
Head Drug Delivery Systems & Parenterals  
  
*Submission and market launch of Buserelin microparticles in Japan*
- 1992 – 1994 : Hoechst AG, Germany, Frankfurt  
Pharmaceutics Department  
Head Special Dosage Forms  
  
*Scale up of microparticle manufacture to industrial scale. Introducing first autoclavable spray dryer in cooperation with Industrial Operation and NIRO to production. External cooperation including pre-financing of new sterile facility with VETTER for double-chamber syringes.*
- 1989 – 1992 : Hoechst AG, Germany, Frankfurt  
Pharmaceutics Department  
Head of Laboratory, Special Dosage Forms  
  
*Formulation & process development for Buserelin microparticles in lab scale including GMP manufacturing. Introducing new excipient (PLGA50:50) to pharma market.*
- 1987 – 1989 : Hoechst AG, Germany, Frankfurt  
Pharmaceutics Department  
Head of Laboratory, Dermal Dosage Forms  
  
*Research program for peptide depot system based on biodegradable microparticles.*
-

Date : 17.09.2015

**4. PROFESSIONAL EXPERIENCE OUTSIDE THE GROUP**

2008 – until now	:	Member of the Scientific Advisory Board; Faculty of Pharmacy, Phillips-University of Marburg, Germany
1985 – 1987	:	Assistant Professor, Pharmaceutical Technology University of Regensburg
1980 – 1981	:	Practical stage in a community pharmacy

**5. Publications / International Associations / Expert Reports (involvements) :****Thesis:**

“Spektroskopische Untersuchungen von Dermatika und Wirkstoffsorbaten an Siliciumdioxid”;  
(Spectroscopic investigations of dermal dosage forms and drug substance adsorbates on silicium dioxide) 1985, University of Regensburg; supervised by Prof. H. Rupprecht

**Publications:**

1. Colloidal silica as drug carrier  
Eckert, Ch; Endres, W; Lill, N; Rupprecht, H; Valentin, B.  
Congr. Int. Technol. Pharm. 5 (240) 1983
2. IR-spektroskopische Untersuchungen an Dermatika mit abgeschwächter totaler Reflexion (ATR-Technik)  
1. Salben und Pflaster  
Lill, N; Rupprecht, H.  
Pharm. Ztg. 129 (690) 1984
3. Spektroskopische Untersuchungen an Phenol-SiO<sub>2</sub>-Sorbaten  
Lill, N; Eckert-Lill, Ch; Rupprecht, H.  
Scentia Pharm. 54 (212) 1986
4. Chemisorbates of drugs on silica:  
A new approach to drug release modification  
Eckert-Lill, Ch; Lill, N; Endres, W; Rupprecht, H.  
Drug Dev. & Industrial Pharmacy 13 (9) 1987
5. Phenylalkanol – adsorbates on silica as types of immobilized drugs  
1. Chemiadsorption on activated silica surfaces  
Eckert-Lill, Ch; Lill, N; Rupprecht, H.  
Colloid & Polymer Sci. 265 (1001) 1987
6. Immobilized drugs: Phenol and benzoic acid derivatives chemiadsorbed on silica.  
I. Preparation of chemiadsorbates.  
Eckert-Lill, Ch.; Lill, N.; Endres, W; Rupprecht, H.  
Acta Pharm. Jugosl. 38/4 (373) 1988

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.